Patents by Inventor Holger Thie

Holger Thie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10730922
    Abstract: The present invention provides a composition comprising i) a polypeptide comprising calmodulin and two immunoglobulin superfamily domains, wherein said two immunoglobulin superfamily domains are linked via said calmodulin; ii) a calmodulin binding molecule; iii) ions binding to the Ca2+ binding site of calmodulin; wherein the binding of said calmodulin-binding molecule and of said ions to said Ca2+ binding site of calmodulin affects the binding of said polypeptide to an antigen to be bound by said polypeptide. The calmodulin may be a permutated calmodulin. A method for affecting the binding of a polypeptide for an antigen using said composition is also disclosed.
    Type: Grant
    Filed: July 14, 2017
    Date of Patent: August 4, 2020
    Assignee: Miltenyi Biotech B.V. & Co. KG
    Inventors: Stefan Dübel, Sarah-Jane Kellmann, Holger Thie
  • Publication number: 20180112000
    Abstract: The present invention provides a humanized antibody or fragment thereof specific for the antigen CD3, wherein said antibody or fragment thereof comprises a heavy chain variable domain comprising a CDR1 region of SEQ ID NO: 1, a CDR2 region of SEQ ID NO:2, and a CDR3 region of SEQ ID NO:3, and a light chain variable domain comprising a CDR1 region of SEQ ID NO:4, a CDR2 region of SEQ ID NO:5, and a CDR3 region of SEQ ID NO:6. In addition, the present invention provides a method for polyclonal stimulation of T cells comprising contacting a population of T cells with said anti-CD3 antibody, optionally with an anti-CD28 antibody, wherein said anti-CD3 antibody and optionally said anti-CD28 antibody are linked to particles. Further said anti-CD3 antibody can be used for reversible tagging of cells.
    Type: Application
    Filed: May 6, 2016
    Publication date: April 26, 2018
    Inventors: Volker NÖLLE, Holger THIE, Andrew KAISER
  • Publication number: 20180030104
    Abstract: The present invention provides a composition comprising i) a polypeptide comprising calmodulin and two immunoglobulin superfamily domains, wherein said two immunoglobulin superfamily domains are linked via said calmodulin; ii) a calmodulin binding molecule; iii) ions binding to the Ca2+ binding site of calmodulin; wherein the binding of said calmodulin-binding molecule and of said ions to said Ca2+ binding site of calmodulin affects the binding of said polypeptide to an antigen to be bound by said polypeptide. The calmodulin may be a permutated calmodulin. A method for affecting the binding of a polypeptide for an antigen using said composition is also disclosed.
    Type: Application
    Filed: July 14, 2017
    Publication date: February 1, 2018
    Inventors: Stefan DÜBEL, Sarah-Jane KELLMANN, Holger THIE
  • Patent number: 9701756
    Abstract: The present invention provides a humanized antibody or fragment thereof specific for the antigen CD45R0, wherein said antibody or fragment thereof comprises a humanized heavy chain variable domain comprising a CDR1 region of SEQ ID NO:1, a CDR2 region of SEQ ID NO:2, and a CDR3 region of SEQ ID NO:3, and a humanized light chain variable domain comprising a CDR1 region of SEQ ID NO:4, a CDR2 region of SEQ ID NO:5, and a CDR3 region of SEQ ID NO:6. It is also provided the use of the present antibody or fragment thereof for enrichment or depletion of CD45R0-expressing cells from a sample comprising CD45R0-expressing cells.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: July 11, 2017
    Assignee: Miltenyi Biotec GmbH
    Inventors: Holger Thie, Stefan Tomiuk, Iris Bürger, Volker Nolle
  • Patent number: 9546217
    Abstract: Antibodies having a high specificity and high affinity towards the human gene product MUC1, which in specific variants is associated with neoplastic cells, i.e. tumor tissue, to the use of the antibodies for medical purposes, i.e. for tumor treatment, and for analytical purposes, e.g. for tumor diagnosis. Compositions comprising the antibodies, e.g. for use in the analytical processes and analysis, to pharmaceutical compositions comprising the antibodies, and to use of the antibodies in the manufacture of pharmaceutical compositions for tumor treatment or for diagnostic purposes.
    Type: Grant
    Filed: July 17, 2009
    Date of Patent: January 17, 2017
    Assignee: MAB FACTORY GMBH
    Inventors: Christian Behrens, Holger Thie, Michael Hust, Lars Toleikis, Thomas Schirrmann, Stefan Dübel, Christophe De Romeuf
  • Patent number: 9518131
    Abstract: The present invention provides for a method for generating a metal ion binding protein, the method comprising a) integrating the amino acid sequence DDD into CDR1 of a light chain variable region of an antibody or fragment thereof; and b) combining the sequence of step a) with a heavy chain variable region of an antibody or fragment thereof; and c) isolating the protein. Also provided is the use of metal ion binding proteins generated by the method of the present invention for isolation and purification of proteins and for the reversible labeling of a target molecule. Also provided is a metal ion binding anti-CD8 protein.
    Type: Grant
    Filed: April 1, 2014
    Date of Patent: December 13, 2016
    Assignee: Miltenyi Biotech GmbH
    Inventors: Holger Thie, Kristina Reck, Volker Nolle
  • Publication number: 20160152733
    Abstract: The present invention provides a humanized antibody or fragment thereof specific for the antigen CD45R0, wherein said antibody or fragment thereof comprises a humanized heavy chain variable domain comprising a CDR1 region of SEQ ID NO:1, a CDR2 region of SEQ ID NO:2, and a CDR3 region of SEQ ID NO:3, and a humanized light chain variable domain comprising a CDR1 region of SEQ ID NO:4, a CDR2 region of SEQ ID NO:5, and a CDR3 region of SEQ ID NO:6. It is also provided the use of the present antibody or fragment thereof for enrichment or depletion of CD45R0-expressing cells from a sample comprising CD45R0-expressing cells.
    Type: Application
    Filed: November 25, 2015
    Publication date: June 2, 2016
    Inventors: Holger THIE, Stefan Tomiuk, Iris Bürger, Volker Nolle
  • Publication number: 20140296491
    Abstract: The present invention provides for a method for generating a metal ion binding protein, the method comprising a) integrating the amino acid sequence DDD into CDR1 of a light chain variable region of an antibody or fragment thereof; and b) combining the sequence of step a) with a heavy chain variable region of an antibody or fragment thereof; and c) isolating the protein. Also provided is the use of metal ion binding proteins generated by the method of the present invention for isolation and purification of proteins and for the reversible labeling of a target molecule. Also provided is a metal ion binding anti-CD8 protein.
    Type: Application
    Filed: April 1, 2014
    Publication date: October 2, 2014
    Inventors: Holger THIE, Kristina Reck, Volker Nolle
  • Publication number: 20110318757
    Abstract: Antibodies having a high specificity and high affinity towards the human gene product MUC1, which in specific variants is associated with neoplastic cells, i.e. tumor tissue, to the use of the antibodies for medical purposes, i.e. for tumor treatment, and for analytical purposes, e.g. for tumor diagnosis. Compositions comprising the antibodies, e.g. for use in the analytical processes and analyses, to pharmaceutical compositions comprising the antibodies, and to use of the antibodies in the manufacture of pharmaceutical compositions for tumor treatment or for diagnostic purposes.
    Type: Application
    Filed: July 17, 2009
    Publication date: December 29, 2011
    Inventors: Christian Behrens, Holger Thie, MIchael Hust, Lars Toleikis, Thomas Schirrmann, Stefan Dübel, Christophe De Romeouf